Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Receivables (2019 - 2025)

Immunocore Holdings' Receivables history spans 4 years, with the latest figure at $74.0 million for Q4 2025.

  • For Q4 2025, Receivables rose 17.41% year-over-year to $74.0 million; the TTM value through Dec 2025 reached $74.0 million, up 17.41%, while the annual FY2025 figure was $74.0 million, 17.41% up from the prior year.
  • Receivables for Q4 2025 was $74.0 million at Immunocore Holdings, down from $75.9 million in the prior quarter.
  • Across five years, Receivables topped out at $75.9 million in Q3 2025 and bottomed at $33.6 million in Q4 2022.
  • The 4-year median for Receivables is $63.1 million (2024), against an average of $61.3 million.
  • The largest annual shift saw Receivables surged 55.11% in 2023 before it increased 9.25% in 2025.
  • A 4-year view of Receivables shows it stood at $33.6 million in 2022, then soared by 55.11% to $52.1 million in 2023, then grew by 20.95% to $63.0 million in 2024, then grew by 17.41% to $74.0 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Receivables are $74.0 million (Q4 2025), $75.9 million (Q3 2025), and $69.8 million (Q2 2025).